Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Plex TCR-T cells in advanced solid tumors
NCT05973487Phase 1Active, not recruiting
- Sponsor
- TScan Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Bone Marrow HSCs, HLA-independent TCR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-203-A0201, TSC-204-A0101 and 2 more in head and neck cancer (HNC), Cervical Cancer (CC), non-small cell lung cancer (NSCLC) and 5 more, sponsored by TScan Therapeutics. Started May 2024; status: active, not recruiting.
02
Drugs
TSC-204-A0201TSC-204-C0702TSC-200-A0201TSC-203-A0201TSC-204-A0101
03
Conditions
head and neck cancer (HNC)Cervical Cancer (CC)non-small cell lung cancer (NSCLC)melanomaovarian cancer
Beyond the preview
Go deeper on NCT05973487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973487.